Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

During the developing COVID-19 pandemic, the Nuffield Department of Medicine Research Building is taking measures to prevent the spread of the disease.

Departments are instructed by the University's Registrar to work from home and manage building closures.

This is to restrict any contact between individuals as far as possible.  The University remains open and operating as far as possible with the following restrictions:

  • Only essential activities should continue on site (e.g. research relating to Covid-19 or that of national importance, or the maintenance of research equipment.  Departments are responsible for defining what is essential, in line with divisional guidance, and should provide appropriate operating procedures.  PVC Research will be in touch with Divisions to assist in drawing up guidance.
  • Other research and teaching continues remotely where possible and students return home (if possible and where that has not already happened)
  • Departments physically close except where essential activities have to be done on site.  Staff work remotely where possible.  Only core support functions and other essential activities continue on site and only with critical staff on site - e.g. building access and maintenance, security, maintenance or research equipment.


Bacteria perform mass suicide to defend their colony

A new study from researchers at Oxford University’s Departments of Zoology and Biochemistry shows that warring bacteria will engage in suicidal attacks in vast numbers to take down competitors.

No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19

A new statement has been released from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine.

Recent publications